Cosmetic & Pharmaceutical
Gaylord National Harbor Hotel, Oxon Hill, MD
(This year's event took place in April)
The 8th Global Orphan Drug Conference and Expo
Strategy, Regulation and Opportunity for Pharma, Biotech and Investors in Rare Diseases
White paper explores the rise of speciality medicines and the challenges presented to the industry in terms of demand, access and supply
A specialist British pharmaceutical wholesaler has published a white paper that explores the global challenges of access to, and delivery of, speciality medicines. In particular it looks at the unique challenges and solutions for the industry in terms of demand, access and supply.
The paper has been released by CHAPPER healthcare in advance of this year’s World Orphan Drug Congress USA, which took place in Washington in April.
Over the last decade many pharma companies have moved from mass-market drug development to investing in niche speciality medicines. This is good news for patients with rare diseases, however, high development costs and lower patient numbers mean the products may not be accessible to all patients due to cost.
“The rise of specialty treatments for chronic, complex and rare conditions has seen many breakthrough treatments being brought to market and offering new hope to patients. However, while each of the last ten years has seen greater spending growth for specialty medicines than their more traditional counterparts, market access has become more complex. Smaller sizes of potential patient populations can often lead to sky high price tags for many of the newer drugs, and this has prompted patients and carers to look for more immediate solutions to help them obtain vital treatments.”.”
CEO, CHAPPER HEALTHCARE
Within the paper, CHAPPER healthcare outlines the approach needed to distribute speciality medicines and the challenges of operating within Europe, including the impact of a post-Brexit European Union.
It also highlights the benefits of Managed Access Programmes (MAPs), and how they could help get drugs to patients faster by providing access to treatments in countries where commercialisation may not be viable or where a formal licence has yet to be issued.
The shift from blockbuster to niche has operated in parallel with the rise of the empowered patient, and increasingly, fund-raising patient advocates which adds further complexity to the landscape. The paper examines this along with the impact of the digital landscape on the consumer.
For over 40 years, CHAPPER healthcare has been improving patients’ access to medicines by successfully supplying pharmaceuticals, including orphan drugs, non-registered medicines and emergency medicines to clients across the world.
The company has an experienced team who pride themselves on delivering exceptional customer service and supplying products safely, securely and on time. The company take pride in their role in improving the health and wellbeing of individuals around the globe.
To arrange an appointment with the team, please contact your account representative or email email@example.com
Management Forum - Pharmaceutical Events
Management Forum Pharmaceutical events have an unrivalled reputation in the industry. Topics cover all aspects of the Pharmaceutical drug development process and our portfolio is are continually being developed to ensure you can keep up to date with all areas relevant to your role.
“Professional, friendly and very patient when dealing with speakers, delegates and me! All I could ask for in a pharmaceutical event management company. That's why we will be back with them next year”
Managing Director, Network Pharma
Rembrandt Hotel, London;
13-14 September 2018
This seminar, presented by a US lawyer with over 40 years of experience dealing with pharmaceutical regulation in the United States and Europe, will provide a general introduction to all aspects of the US drug approval process.
It will also cover the organisation and structure of the Food and Drug Administration, recent amendments to the FDA’s procedures designed to expedite the testing and approval of new medicines and other topics of current interest.
Previous customers/attendees include:
- Auden McKenzie Group, DSTL, Eli Lilly Regional Operations GmbH
- Grifols, S.A., GW Pharmaceuticals, Hookipa Biotech AG, ImmuPharma
- Leo Pharma A/S, LFB Biomedicaments, MedImmune Limited, Molnlycke Healthcare, NDA Regulatory Science Ltd, Orion Corporation Orion Pharma
- and Pharma Mar, S.A.
Pharmacovigilance Aspects of Licensing Agreements
An essential course for all those involved in drug safety and licensing agreements
2 October 2018
Rembrandt Hotel, London
Issues to be addressed during this seminar:
- Making sense of the licensing agreement jungle
- How to stay compliant with global pharmacovigilance requirements n Understand what the regulators expect
- Essentials of licensing agreements - safety and business
- Understand the legal status and role of pharmacovigilance licensing
- Discuss audit and compliance aspects of third party agreements n Practical approaches and challenges
Abridged Applications, The Regulator and the Industry view, an intensive course examinig the current requirements and current problems for those with a basic knowledge of the application procedure.
A 14 module self-managed, flexible, online learning course: Focus on the essential MBA theory, practice and technique needed to be a high-performing manager in the field of pharmaceutical with this 14 module course allowing 3 to 4 hours per module to be completed in your own time.